Concert Pharmaceuticals, Inc. (CNCE): Price and Financial Metrics

CNCE POWR Grades

• CNCE scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.14% of US stocks.
• The strongest trend for CNCE is in Stability, which has been heading up over the past 64 days.
• CNCE ranks lowest in Momentum; there it ranks in the 8th percentile.

CNCE Stock Summary

• Of note is the ratio of Concert Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 7.98% of US stocks have a lower such ratio.
• The ratio of debt to operating expenses for Concert Pharmaceuticals Inc is higher than it is for about merely 15.88% of US stocks.
• As for revenue growth, note that CNCE's revenue has grown 312.27% over the past 12 months; that beats the revenue growth of 97.42% of US companies in our set.
• If you're looking for stocks that are quantitatively similar to Concert Pharmaceuticals Inc, a group of peers worth examining would be SGMO, NRIX, PTGX, XENE, and ANAB.
• CNCE's SEC filings can be seen here. And to visit Concert Pharmaceuticals Inc's official web site, go to www.concertpharma.com.

CNCE Valuation Summary

• In comparison to the median Healthcare stock, CNCE's EV/EBIT ratio is 100.68% lower, now standing at -0.2.
• Over the past 92 months, CNCE's price/sales ratio has gone down 5.5.
• Over the past 92 months, CNCE's price/sales ratio has gone down 5.5.

Below are key valuation metrics over time for CNCE.

CNCE Growth Metrics

Its 3 year net income to common stockholders growth rate is now at -480.32%.
• Its 5 year cash and equivalents growth rate is now at 23.59%.
• Its year over year revenue growth rate is now at 9900%.

CNCE's revenue has moved up $31,547,000 over the prior 34 months.

The table below shows CNCE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	32.578	-55.154	-80.051
2021-09-30	32.572	-44.904	-66.312
2021-06-30	33.53	-46.553	-58.542
2021-03-31	7.9	-71.917	-76.958
2020-12-31	7.902	-69.037	-74.766
2020-09-30	7.908	-67.885	-72.863

CNCE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CNCE has a Quality Grade of B, ranking ahead of 78.61% of graded US stocks.
• CNCE's asset turnover comes in at 0.223 -- ranking 188th of 680 Pharmaceutical Products stocks.
• SRNE, VBLT, and ISEE are the stocks whose asset turnover ratios are most correlated with CNCE.

The table below shows CNCE's key quality metrics over time.